Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Tremelimumab in BRCA-Mutated Recurrent Ovarian Cancer
NCT02571725Phase 2Active, not recruiting
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Feb 2016
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in ovarian cancer, fallopian tube cancer (PFTC) and peritoneal neoplasm, sponsored by New Mexico Cancer Research Alliance. Primary endpoints: Recommended Phase 2 Dose at 56 days and Objective Response Rate at 2 years. Started Feb 2016; status: active, not recruiting.
02
Drugs
tremelimumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)peritoneal neoplasm
Beyond the preview
Go deeper on NCT02571725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571725.